Microglial Activation Mediates Noradrenergic Locus Coeruleus Neurodegeneration via Complement Receptor 3 in a Rotenone-Induced Parkinson's Disease Mouse Model.
CR3
Parkinson’s disease
locus coeruleus
neuroinflammation
noradrenergic neuron
pesticide
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
01
2021
accepted:
24
03
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
17
4
2021
Statut:
epublish
Résumé
Chronic exposure to the insecticide rotenone can damage dopaminergic neurons and lead to an increased risk of Parkinson's disease (PD). Whereas it is not clear whether rotenone induces neurodegeneration of noradrenergic locus coeruleus (LC/NE) neurons. Chronic neuroinflammation mediated by microglia has been involved in the pathogenesis of PD. Evidence shows that complement receptor 3 (CR3) is a crucial regulator of microglial activation and related neurodegeneration. However, it is not clear whether CR3 mediates rotenone-elicited degeneration of LC/NE neurons through microglia-mediated neuroinflammation. Wild type (WT) and CR3 knockout (KO) mice were treated with rotenone. PLX3397 and minocycline were used to deplete or inactivate the microglia. Leukadherin-1 (LA-1) was used to modulate CR3. LC/NE neurodegeneration, microglial phenotype, and expression of CR3 were determined by using immunohistochemistry, Western blot and real-time polymerase chain reaction (PCR) techniques. The glutathione (GSH) and malondialdehyde (MDA) contents were measured by using commercial kits. Rotenone exposure led to dose- and time-dependent LC/NE neuronal loss and microglial activation in mice. Depletion of microglia by PLX3397 or inhibition of microglial activation by minocycline significantly reduced rotenone-induced LC/NE neurodegeneration. Mechanistic studies revealed that CR3 played an essential role in the rotenone-induced activation of microglia and neurodegeneration of LC/NE neurons. Rotenone elevated the expression of CR3, and genetic ablation of CR3 markedly reduced rotenone-induced microglial activation and M1 polarization. LA-1 also suppressed rotenone-induced toxic microglial M1 activation. Furthermore, lack of CR3 or treatment with LA-1 reduced oxidative stress in the brainstem of rotenone-intoxicated mice. Finally, we found that mice deficient in CR3 or treated with LA-1 were more resistant to rotenone-induced LC/NE neurodegeneration than WT or vehicle-treated mice, respectively. Our results indicate that CR3-mediated microglial activation participates in rotenone-induced LC/NE neurodegeneration, providing novel insight into environmental toxin-induced neurotoxicity and related Parkinsonism.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic exposure to the insecticide rotenone can damage dopaminergic neurons and lead to an increased risk of Parkinson's disease (PD). Whereas it is not clear whether rotenone induces neurodegeneration of noradrenergic locus coeruleus (LC/NE) neurons. Chronic neuroinflammation mediated by microglia has been involved in the pathogenesis of PD. Evidence shows that complement receptor 3 (CR3) is a crucial regulator of microglial activation and related neurodegeneration. However, it is not clear whether CR3 mediates rotenone-elicited degeneration of LC/NE neurons through microglia-mediated neuroinflammation.
MATERIALS AND METHODS
METHODS
Wild type (WT) and CR3 knockout (KO) mice were treated with rotenone. PLX3397 and minocycline were used to deplete or inactivate the microglia. Leukadherin-1 (LA-1) was used to modulate CR3. LC/NE neurodegeneration, microglial phenotype, and expression of CR3 were determined by using immunohistochemistry, Western blot and real-time polymerase chain reaction (PCR) techniques. The glutathione (GSH) and malondialdehyde (MDA) contents were measured by using commercial kits.
RESULTS
RESULTS
Rotenone exposure led to dose- and time-dependent LC/NE neuronal loss and microglial activation in mice. Depletion of microglia by PLX3397 or inhibition of microglial activation by minocycline significantly reduced rotenone-induced LC/NE neurodegeneration. Mechanistic studies revealed that CR3 played an essential role in the rotenone-induced activation of microglia and neurodegeneration of LC/NE neurons. Rotenone elevated the expression of CR3, and genetic ablation of CR3 markedly reduced rotenone-induced microglial activation and M1 polarization. LA-1 also suppressed rotenone-induced toxic microglial M1 activation. Furthermore, lack of CR3 or treatment with LA-1 reduced oxidative stress in the brainstem of rotenone-intoxicated mice. Finally, we found that mice deficient in CR3 or treated with LA-1 were more resistant to rotenone-induced LC/NE neurodegeneration than WT or vehicle-treated mice, respectively.
CONCLUSION
CONCLUSIONS
Our results indicate that CR3-mediated microglial activation participates in rotenone-induced LC/NE neurodegeneration, providing novel insight into environmental toxin-induced neurotoxicity and related Parkinsonism.
Identifiants
pubmed: 33859489
doi: 10.2147/JIR.S299927
pii: 299927
pmc: PMC8044341
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1341-1356Informations de copyright
© 2021 Jing et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Mol Neurobiol. 2019 Apr;56(4):2653-2669
pubmed: 30051353
J Neuroimmune Pharmacol. 2017 Sep;12(3):433-446
pubmed: 28429275
Immunol Rev. 2016 Jan;269(1):175-93
pubmed: 26683153
J Neurochem. 2006 Feb;96(3):706-18
pubmed: 16405514
Redox Biol. 2019 Jun;24:101164
pubmed: 30925294
Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:39-47
pubmed: 27619637
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14669-74
pubmed: 11724929
Front Aging Neurosci. 2017 Jun 08;9:176
pubmed: 28642697
Mol Neurodegener. 2018 Mar 1;13(1):11
pubmed: 29490706
FASEB J. 2003 Oct;17(13):1954-6
pubmed: 12897068
Brain. 2015 May;138(Pt 5):1247-62
pubmed: 25716193
Neuropsychopharmacology. 2007 Dec;32(12):2570-80
pubmed: 17356569
Electrophoresis. 2009 Jun;30(11):1845-55
pubmed: 19517440
Antioxid Redox Signal. 2020 Aug 10;33(5):374-393
pubmed: 31968994
Brain Behav Immun. 2020 Jan;83:226-238
pubmed: 31626970
Cell Tissue Res. 2004 Oct;318(1):121-34
pubmed: 15338272
Front Cell Neurosci. 2019 Jan 09;12:529
pubmed: 30687016
Neuroscience. 2019 Nov 1;419:129-140
pubmed: 31634513
Mol Neurobiol. 2016 Jul;53(5):2761-2777
pubmed: 25764516
Toxicology. 2017 Apr 1;380:1-10
pubmed: 28202386
Neurosci Lett. 2003 May 1;341(2):87-90
pubmed: 12686372
Science. 2016 May 6;352(6286):712-716
pubmed: 27033548
Neuron. 2014 Apr 16;82(2):380-97
pubmed: 24742461
Biomed Res Int. 2019 Mar 5;2019:6843265
pubmed: 30949504
FEBS Lett. 2014 Jan 31;588(3):472-81
pubmed: 24374334
Nat Rev Neurosci. 2007 Jan;8(1):57-69
pubmed: 17180163
J Neuroinflammation. 2021 Jan 5;18(1):4
pubmed: 33402167
Glia. 2019 Feb;67(2):277-290
pubmed: 30565754
Neuroscience. 2015 Apr 30;292:46-70
pubmed: 25592425
Neuropharmacology. 2018 Jul 15;137:240-255
pubmed: 29738851
Am J Physiol Gastrointest Liver Physiol. 2015 Jan 15;308(2):G151-8
pubmed: 25428903
Neurobiol Dis. 2018 Jul;115:101-114
pubmed: 29649621
J Biochem Mol Toxicol. 2013 Feb;27(2):137-49
pubmed: 23349115
Toxicology. 2019 Apr 1;417:64-73
pubmed: 30797899
Curr Alzheimer Res. 2016;13(12):1319-1329
pubmed: 27539598
Antioxid Redox Signal. 2005 May-Jun;7(5-6):654-61
pubmed: 15890010
Toxicol Sci. 2019 Feb 1;167(2):397-407
pubmed: 30247689
Pharmacol Rep. 2019 Feb;71(1):32-41
pubmed: 30368226
Amino Acids. 2018 May;50(5):547-556
pubmed: 29508060
Neural Regen Res. 2018 Aug;13(8):1332-1337
pubmed: 30106035
Brain Behav Immun. 2019 Oct;81:374-387
pubmed: 31247288
Int Neurourol J. 2018 Oct;22(Suppl 3):S147-155
pubmed: 30396264
Redox Biol. 2019 Apr;22:101134
pubmed: 30798073
Redox Biol. 2018 Apr;14:250-260
pubmed: 28978491
Toxicol Lett. 2020 Oct 1;331:152-158
pubmed: 32522579
BMC Neurosci. 2016 Aug 22;17(1):58
pubmed: 27549180
Int J Biochem Cell Biol. 2016 Jun;75:34-44
pubmed: 27012437
Neurobiol Learn Mem. 2011 Mar;95(3):296-304
pubmed: 21167950
Redox Biol. 2018 Apr;14:600-608
pubmed: 29154191
Neurotoxicology. 2018 Mar;65:9-21
pubmed: 29360531
Mol Neurodegener. 2009 Dec 31;4:55
pubmed: 20042120
FASEB J. 2004 Mar;18(3):589-91
pubmed: 14734632
J Neurosci. 2014 Sep 10;34(37):12490-503
pubmed: 25209287
PLoS One. 2013 Aug 20;8(8):e72046
pubmed: 23977201
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):313-22
pubmed: 21658306
Pathophysiology. 2016 Jun;23(2):123-34
pubmed: 26996500
Glia. 2018 Jan;66(1):34-46
pubmed: 28722234
Arch Neurol. 2003 Mar;60(3):337-41
pubmed: 12633144
J Neuroinflammation. 2020 May 6;17(1):148
pubmed: 32375810
Sci Signal. 2011 Sep 6;4(189):ra57
pubmed: 21900205
J Exp Med. 2017 Apr 3;214(4):1081-1092
pubmed: 28298456
Front Neurosci. 2019 Jul 17;13:721
pubmed: 31379480
Brain Behav Immun. 2019 Aug;80:777-792
pubmed: 31108168
Environ Health Perspect. 2011 Jun;119(6):866-72
pubmed: 21269927
Cell Death Dis. 2018 Jan 19;9(2):60
pubmed: 29352205
Cell Death Dis. 2018 Mar 22;9(4):435
pubmed: 29568078
Nat Med. 1999 Dec;5(12):1403-9
pubmed: 10581083
Semin Cell Dev Biol. 2019 Oct;94:112-120
pubmed: 31077796
Neuron. 2014 Apr 2;82(1):195-207
pubmed: 24631344
J Neurosci. 2011 Jan 19;31(3):1081-92
pubmed: 21248133
Drug Des Devel Ther. 2015 Oct 07;9:5499-510
pubmed: 26504373
Nat Neurosci. 2000 Dec;3(12):1301-6
pubmed: 11100151
FASEB J. 2018 Jun;32(6):3336-3345
pubmed: 29401614